BULgarian Carotid Artery Stenting versus Surgery Study (BULCASSS): Randomized single center trial

Similar documents
Carotid Artery Stenting Versus

Carotid Artery Stenosis

CAROTID STENTING A 2009 UPDATE. Hoang Duong, MD Director of Interventional Neuroradiology Memorial Regional Hospital

Carotid Artery Stenting

CLINICAL TIMELINE EVA-3S CREST ICSS SPACE SAPPHIRE

Carotid Endarterectomy vs. Carotid artery Stenting (Surgeon Perspective)

Carotid Artery Stent: Is it ready for prime time?

AN ASSESSMENT OF INTER-RATER RELIABILITY IN THE TREATMENT OF CAROTID ARTERY STENOSIS

MEET Θ symptomatic patients. K. Mathias Department of Radiology Teaching Hospital of Dortmund - Germany

How to Choose Between Carotid Stenting and Carotid Endarterectomy for Stroke Prevention

ICSS Safety Results NOT for PUBLICATION. June 2009 ICSS ICSS ICSS ICSS. International Carotid Stenting Study: Main Inclusion Criteria

Carotid Artery Stenting

03/30/2016 DISCLOSURES TO OPERATE OR NOT THAT IS THE QUESTION CAROTID INTERVENTION IS INDICATED FOR ASYMPTOMATIC CAROTID OCCLUSIVE DISEASE

Treatment Considerations for Carotid Artery Stenosis. Danielle Zielinski, RN, MSN, ACNP Rush University Neurosurgery

UPMC HAMOT CAROTID ARTERY DISEASE WHERE DO WE GO FROM HERE?

ESC Congress 2011 SIMULTANEOUS HYBRID REVASCULARIZATION OF CAROTID AND CORONARY DISEASE INITIAL RESULTS OF A NEW THERAPEUTIC APPROACH

Carotid artery stenting in the elderly: the time has come

Carotid Artery Stenting Today: A Few Updating Remarks

Surgical Treatment of Carotid Disease

DESCRIPTION: Percent of asymptomatic patients undergoing CEA who are discharged to home no later than post-operative day #2

New Trials in Progress: ACT 1. Jon Matsumura, MD Cannes, France June 28, 2008

Algorithmic selection of emboli protection device during the procedure of carotid artery stunting

2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY

Carotid Endarterectomy versus Carotid Angioplasty Cui Bono *

CAROTID ARTERY ANGIOPLASTY

I have the following potential conflicts of interest to report. honorarium: 1. St Jude Medical 2. Biotronik 3. Boston Scientific

Peter A. Soukas, M.D., FACC, FSVM, FSCAI, RPVI

The Great Swedish Debate. Håkan Pärsson Department Vascular Surgery Helsingborgs Lasarett, University Lund

2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Outcome

Extracranial Carotid Artery Stenting With or Without Distal Protection Device

ORIGINAL CONTRIBUTION

Carotid Artery Disease How the Data Will Influence Management The Symptomatic vs. the Asymptomatic Patient

Cerebral Protection for Carotid Artery Stenting: Safety, Efficacy and Limitations

CardioLucca2014. Fare luce sulla scelta ottimale del trattamento nella rivascolarizzazione delle stenosi carotidee. Fabrizio Tomai

Carotid Artery Disease and What s Pertinent JOSEPH A PAULISIN DO

MORTALITY AND MORBIDITY RISK FROM CAROTID ARTERY ATHEROSCLEROSIS. 73 year old NS right-handed male applicant for $1 Million life insurance

Carotid artery percutaneous treatment: back to the future Alberto Cremonesi MD, FESC

More than strokes occur

MORTALITY AND MORBIDITY RISK FROM CAROTID ARTERY ATHEROSCLEROSIS. 73 year old NS right-handed male applicant for $1 Million Life Insurance

Percutaneous transluminal angioplasty and stenting for carotid artery stenosis (Review)

William A. Gray MD System Chief of Cardiovascular Services, Main Line Health President, Lankenau Heart Institute Wynnewood, PA USA

Vivek R. Deshmukh, MD Director, Cerebrovascular and Endovascular Neurosurgery Chairman, Department of Neurosurgery Providence Brain and Spine

Lecture Outline: 1/5/14

Carotid artery stents and embolic protection

Assessment of the procedural etiology of stroke resulting from carotid artery stenting

Carotid. The. Issue. Now approved by the FDA, carotid stenting moves into the spotlight in endovascular care.

TCAR: TransCarotid Artery Revascularization Angela A. Kokkosis, MD, RPVI, FACS

Disclosures. State of the Art Management of Carotid Stenosis. NIH funding for clinical trials Consultant for Scientia Vascular and Medtronic

Carotid Artery Revascularization: Current Strategies. Shonda Banegas, D.O. Vascular Surgery Carondelet Heart and Vascular Institute September 6, 2014

Update : Carotid Stenting and Current Trial Data

Update on current registries and trials of carotid artery angioplasty and stent placement

Articles. Funding Medical Research Council, the Stroke Association, Sanofi-Synthélabo, European Union.

The CARENET all-comer trial using the CGuard micronet covered carotid embolic prevention stent

Small in-stent Low Density on CT Angiography after Carotid Artery Stenting

Recanalization of Chronic Carotid Artery Occlusion Objective Improvement Of Cerebral Perfusion

Post-op Carotid Complications A Nursing Perspective of What to Watch Out for

My work in the field of Carotid Revascularisation

Current Status and Perspectives of ACST-2, CREST-2, ECST-2 and ACTRIS. Richard Bulbulia Co-Principal Investigator ACST-2 University of Oxford

Why I do not believe the

C arotid endarterectomy has been shown to be superior to

Wael Tawfick Sherif Sultan UCHG, NUIG, RCSI

Carotid Artery Stenting (CAS) Pathophysiology. Technical Considerations. Plaque characteristics: relevant concepts. CAS and CEA

Carotid stenosis management: CAS or CEA? Yaoguo Yang, Chen Zhong Beijing Anzhen Hospital,China

PrOspective multicenter study of carotid artery stenting Usinng mer Stent OCEANUS study!!!

Will guidelines and clinical practice for asymptomatic stenosis change in the near future?

Internal carotid artery near-total occlusions: Is it justified to operate on them?

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Outcome

New concepts for filter protection during CAS: double filtration. Alberto Cremonesi MD, FESC

Which Patients Are Good Candidates for Carotid Artery Stenting or Carotid Endarterectomy

Contemporary Management of Carotid Disease What We Know So Far

Alma Mater Studiorum Università di Bologna

CANADIAN STROKE BEST PRACTICE RECOMMENDATIONS

Issam D. Moussa, MD. Professor of Medicine Mayo Clinic College of Medicine Chair, Division of Cardiovascular Diseases Mayo Clinic Jacksonville, FL

Index. interventional.theclinics.com. Note: Page numbers of article titles are in boldface type.

a physician-initiated study investigating the RoadSaver stent in carotid lesions Dr. Michel Bosiers

The Carotid Revascularization Endarterectomy vs. Stenting Trial completes randomization: Lessons learned and anticipated results

Endovascular treatment of the subclavian arteries steno-occlusive disease

Tailored carotid artery stenting

RCSIsmjoriginal article

Predictors of restenosis and cardiovascular events in patients undergoing percutaneous angioplasty for subclavian/innominate artery stenosis

Update on Carotid Stenting. John R. Laird Cardiovascular Research Institute Washington Hospital Center

Two major randomised trials concerning the surgical treatment of carotid artery stenosis

Review of clinical carotid stent procedural & long-term outcomes in. symptomatic asymptomatic. patients

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Extracranial Carotid Artery/Stenting

Asymptomatic Carotid Stenosis To Do or Not To Do

Ossama Yassin Mansour

The argument against revascularization for asymptomatic carotid stenosis

ESC Heart & Brain Workshop

Dr Julia Hopyan Stroke Neurologist Sunnybrook Health Sciences Centre

Endovascular treatment for pseudoocclusion of the internal carotid artery

Filters versus Occlusion Balloons during CAS Is there a clear preference?

CAROTID ANGIOPLASTY AND STENTING UNDER PROTECTION IS BECOMING THE GOLD STANDARD TREATMENT IN HIGH AND LOW RISK PATIENTS

Slide 1. Slide 2 Conflict of Interest Disclosure. Slide 3 Stroke Facts. The Treatment of Intracranial Stenosis. Disclosure

Extracranial Carotid Artery/Stenting

Advances in the treatment of posterior cerebral circulation symptomatic disease

AN EXPERIENCE WITH ANGIOPLASTY AND STENTING OF CAROTID ARTERY STENOSIS WITH EMBOLIC PROTECTION DEVICES

Special Topic Section

Management of Carotid Disease CHRISTOPHER LAU PGY-3 BROOKLYN VA

Transcription:

BULgarian Carotid Artery Stenting versus Surgery Study (): Randomized single center trial Ivo Petrov, M. Konteva, H. Dimitrov, K. Kichukov Tokuda Hospital Sofia Cardiology Department

Background Carotid artery stenting (CAS) has shown in several trials no inferiority to the carotid endartherectomy (CEA) for patients with carotid stenosis. Still a debate persist about the safety and efficacy of CAS compared to CEA. This constant argument is substantially powered by the results of clinical trials that have lot of limitations : The low complication rate of CEA is based on ACAS, NASCET, ECST trials with highly selected study groups, low risk patients, high volume participating operators and institutions. After the promising for CAS results of the CAVATAS 1 and SAPPHIRE 2,3 trials, the intermediate results of SPACE 4 and the unsatisfactory results of EVA 3S shook the scientific community, but EVA 3S 5 had great limitations: vascular surgeon at least 25 endarterectomies performed in the year before enrollment. interventional physician at least 5 stenting procedures in the carotid artery performed altogether. Multiple therapeutic devices 5 types of stents and 7 types of EPD. The first procedures were performed without mandatory EPD with catastrophic results Only 85.4% of the pts had dual antiplatelet therapy post procedure. 1. CAVATAS Investigators. Endovascular versus surgical treatment (CAVATAS). Lancet. 2001; 357: 1729 1737 2. JS. Yadav, Protected Carotid Artery Stenting versus Endarterectomy in High Risk Patients. N Engl J Med, 2004, 351;15 3. Gurm HS, Yadav JS et allong Term Results of Carotid Stenting versus Endarterectomy in High Risk Patients N Engl J Med 358:1572, April 10, 2008 4. 30 day results from the SPACE trial. The Lancet 2006; 368:1239 1247 5. Jean Louis Mas et al. Endarterectomy versus Stenting in Patients with Symptomatic Severe Carotid Stenosis. N Engl J Med 2006;355:1660 71.

Background Many of the randomized trials present a significant bias from the real clinical practice comparing highly selected populations The using of historic control groups leads to rough comparison between high risk CAS procedures vs low risk surgical procedures

The need for a real life study In the era of evidence based medicine there is a substantial need of not only randomized clinical trials with high selective criteria but trials that bring the real life situation into science. Such a trial should compare CAS and CEA not only in selected patients but also in broad range of risk asymptomatic/ symptomatic patients. We designed and conducted a prospective, randomized, single center trial comparing CAS to standard CEA in patients with asymptomatic and symptomatic carotid stenosis without selection criteria about the risk profile. Patients were enrolled using unified selection criteria and the enrollment ratio was designed to be 1:2 (CAS to CEA) for the first 50 patients and 1:1 afterwords.

The need for a real life study Endpoints Primary endpoint: Comparative periprocedural incidence of any nonfatal stroke, acute myocardial infarction (AMI), transitory ischemic attack (TIA), death (combined MAE) and stroke and death for a 3 year follow up Secondary end points: Comparison of length of hospital stay Comparison of CAS procedures with and without distal EPD Analysis of the restenosis in the CAS group

Patient randomization schedule

Study design Between February 2001 and December 2004 in a single clinical center 219 patients were randomly assigned to either CAS or CEA : 101 were treated with CAS and 118 with CEA. CEA was performed by two operators with more than 200 cases individual previous experience. CAS single operator with more than 100 CAS procedures previous experience. 4 types of EPD (EPI filterwire, Angioguard, Spider, Guardwire), 4 types of stents (1 BE: Palmaz and 3 SE: Protégé, Precise, X act) Patients baseline characteristics Index CAS n= 101 СЕА n= 118 n % n % Р Value Males 79 78.2 99 83.9 0.129 ns Age > 70 years 23 22.7 25 21.18 1.000 ns Mean age 62.47 ± 8.41 NA 63.94 ± 8.707 NA 0.206 ns Diabetics 29 28.7 39 33.0 0.870 ns Hypertension 95 94.05 108 91.5 1.000 ns Dyslipidemia 64 63.36 79 66.95 1.000 ns History of smoking 50 49.5 62 52.5 1.000 ns Arteriitis 2 1.9 1 0.8 1.000 ns

. Study design Baseline clinical characteristics Index CAS n= 101 СЕА n= 118 n % n % Multivessel involvement 78 77.22 83 70.3 ns CAD 69 68.3 71 60.1 ns Peripheral artery disease 16 15.8 18 15.2 ns Neurologically symptomatic 59 58.4 72 61.1 ns TIA 27 26.7 37 31.3 ns Ischaemic stroke 34 33.6 35 29.6 ns Neurologically asymptomatic 42 41.5 46 38.9 ns Subtotal occlusion 10 9.9 11 9.3 ns P value

Periprocedural results Entire population Index CAS n=101 CEA n=118 P value Ipsilateral stroke 2 2.0% 3 2.5% 1.000 ns AMI 1 1.0% 1 0.8% 1.000 ns Death 1 1.0% 1 0.8% 1.000 ns ТIA 7 6.9% 7 5.9% 0.788 ns МАЕ 9 8.9 % 12 10.2% 0.821 ns

Periprocedural results Patients age over 70 Index CAS n=23 CEA n=30 P Value Ipsilateral stroke 1 4.3% 2 6.7% 1.000 ns AMI 1 4.3% 0 0% 0.434 ns Death 1 4.3% 1 3.35% 1.000 ns МАЕ 6 26.1% 6 22.6% 0.743 ns ТIA 5 21.7% 3 10% 0.272 ns

Periprocedural results Diabetic patients Index CAS n=29 СЕА n=39 P Value Ipsilateral stroke 1 3.4% 1 2.6% 1.000 ns AMI 0 0% 1 2.6% 1.000 ns Death 0 0% 1 2.6% 1.000 ns МАЕ 4 13.8 % 4 10.3% 0.715 ns ТIA 3 10.3% 1 2.6% 0.305 ns

BULCASS Length of Hospital Stay Patient group Hospital stay (Days) P Value CAS n=100 3.94 ± 3.40 p< 0.005 9.50±4.91 CEA n= 117

CAS subanalysis. Early results EPD vs no EPD Index EPD n=94 W/o EPD n=7 р 0 % 2 Ipsilateral stroke 0 28.6 % 0.040 AMI 0 Death 0 ТIA 6 0 % 1 0 % 1 6.3 % 1 14.3 % 14.3 % 14.3 % 0.069 ns 0.069 ns 0.405 ns МАЕ 6 6.3 % 3 42.8 % 0.015

Late results 3 year follow up Index CAS n=100 CEA n=117 P Value Ipsilateral stroke 4 4.0% 5 4.2% 1.000 ns AMI 4 4.0% 5 4.2% 1.000 ns Death 6 6.0% 11 9.2% 0.450 ns МАЕ 9 9.0 % 16 13.6% 0.297 ns Restenosis 4 3.9 % 5 4.2 % 1.000 ns

Early procedural and late results after 3 year follow up

CAS subanalysis. Late results. SE vs BE stents Index Stent type Self exp. n= 83 Balloon exp. n= 14 n % n % р Ipsilateral stroke 2 2.4 2 14.3 0.098 ns Restenosis 1 1.2 3 21.4 0.009 Death 4 4.8 1 7.1 0.549 ns LМАЕ 6 7.2 2 14.3 0.325 ns

Conclusions In experienced hands and using appropriate materials, both methods CEA and CAS could be performed at low mortality and morbidity rate This study suggests that the incidence of nonfatal stroke, death, TIA and combined MAE following carotid stenting is statistically equivalent to carotid endartherectomy. The interventional carotid treatment is associated with a significantly shorter hospital stay. The preventive role of both methods regarding stroke rate are equivalent. The balloon expandable stents are not suitable for CAS, confirmed by other studies 1 The use of distal EPD during CAS is mandatory 1. Iyer SS, Roubin GS, Yadav Js et al: Extracranial Carotid artery stenting: balloon expandable versus self expanding stents. Circulation 1996; 94(Suppl I): 485

final remarks The study represents a real life situation without pre selection bias for either arm CAS or CEA based on low or high operative risk, symptomatic or asymptomatic carotid lesion. Limitations of the study Low number of the study population

Thank you for your attention!